Anthem Biosciences Limited IPO Review
Neutral540-570 · Mainboard
✦
Analyst Verdict
Anthem Biosciences Limited IPO
Neutral
IPO at a Glance
Price Band
540-570
Issue Size
3395cr
Opens
2025-07-12
Closes
2025-07-14
Listing
2025-07-19
Category
Mainboard
Key Strengths
✓Comprehensive services across the drug life cycle for small molecules and biologics
✓Focus on advanced solutions across modalities and manufacturing practices
✓Specialised model for small pharmaceutical and biotech companies
✓Established customer base with ongoing relationships
✓Experienced leadership and skilled scientific team
Key Risks
⚠Failure to develop new or improve existing technologies.
⚠Delays in obtaining regulatory approvals.
⚠Under-utilisation of manufacturing capacity and demand forecasting issues.
⚠Pricing pressures affecting product prices and profitability.
⚠Risks from data security breaches and failure to safeguard sensitive information.
⚠Seasonality affecting business performance and cash flow.
Frequently Asked Questions
Should I apply for Anthem Biosciences Limited IPO?
Based on our analysis, our rating for Anthem Biosciences Limited IPO is: Neutral. Review the full analysis including strengths, risks, and financials on CheckIPO before making a decision.
What are the key risks of Anthem Biosciences Limited IPO?
Failure to develop new or improve existing technologies. Delays in obtaining regulatory approvals. Under-utilisation of manufacturing capacity and demand forecasting issues.
What are the strengths of Anthem Biosciences Limited IPO?
Comprehensive services across the drug life cycle for small molecules and biologics Focus on advanced solutions across modalities and manufacturing practices Specialised model for small pharmaceutical and biotech companies
What is the price band of Anthem Biosciences Limited IPO?
The price band for Anthem Biosciences Limited IPO is 540-570. The IPO has closed.
Full Analysis Available
Financials, DRHP breakdown, peer comparison, shareholding pattern & more